Moderna Is Losing Billions. Here's Why That Might Be Exactly the Right Strategy.

Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]The ...

Moderna secures up to $50 million to develop an Ebola vaccine.

Oxford University and Moderna to trial pioneering cancer vaccine - ...

Oxford and Moderna’s preventive mRNA cancer vaccine enters trials, targeting high-risk Lynch syndrome patients to train ...

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's ...

eCommerce Powered by FFF Enterprises™ delivers an enhanced ordering experience for Moderna customers. Built on BioSupply®, FFF Enterprises’ proprietary ecommerce platform, the Moderna Direct site ...

CEPI is committing up to $50 million to support Moderna's vaccine candidate for the strain with no approved shot ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

AFP / Moderna shares are surging after a report the drugmaker confirmed it's working on a potential hantavirus vaccine. Several people have tested positive for the rare hantavirus on the cruise ship ...